ArticleBioinformation2026
Human mesenchymal stem cell differentiation on bioactive glass-coated implants.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Successful osseointegration of titanium implants remains a major challenge because the ideal bioactive surface coating and its specific influence on stem cell osteogenic differentiation are not yet fully understood. Therefore, it is of interest to evaluate the effect of bioactive glass (BG) coatings on the osteogenic differentiation of human bone marrow mesenchymal stem cells cultured on titanium implant discs. Forty-eight commercially pure titanium discs were divided into four groups (n = 12 each): uncoated control, 45S5 BG-coated, strontium-substituted BG-coated (Sr-BG) and zinc-substituted BG-coated (Zn-BG) and assessed at days 7, 14 and 21 for cell viability, alkaline phosphatase activity, osteocalcin expression, mineralized nodule formation and expression of RUNX2, COL1A1, OCN and OPN. All BG- coated groups demonstrated significantly greater cell viability, ALP activity and mineralized calcium deposition than the uncoated control (p < 0.05), while the Sr-BG group showed the highest RUNX2 and osteocalcin gene expression at day 21 (p < 0.001), followed by the Zn- BG group. Bioactive glass coating, particularly strontium-substituted BG, significantly enhanced osteogenic differentiation of hBMSCs on titanium surfaces and may improve the clinical success of osseointegration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.